PaxMedica (MEX:PXMD) Stock Based Compensation: MXN37.08 Mil (TTM As of Sep. 2024)


MEX:PXMD PaxMedica Inc MEX:PXMD
20 GF Score
Price MXN15.69
View Full Analysis

What is PaxMedica Stock Based Compensation?

PaxMedica MEX:PXMD 20 Stock Based Compensation is MXN37.08 Mil as of Sep. 2024. GuruFocus rates MEX:PXMD with a GF Score™ of 20/100.

PaxMedica's Stock Based Compensation for the three months ended in Sep. 2024 was MXN0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 was MXN37.08 Mil.

PaxMedica Stock Based Compensation Related Terms

PaxMedica Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for PaxMedica's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PaxMedica Stock Based Compensation Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial 0.00 45.00 27.41 86.13 88.35

PaxMedica Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.55 11.97 25.11 0.00 0.00
MEX:PXMD
20GF Score
PaxMedica Inc MEX:PXMD
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PaxMedica Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN37.08 Mil.

What does a Stock Based Compensation of MXN37.08 Mil mean?
PaxMedica (MEX:PXMD) has a Stock Based Compensation of MXN37.08 Mil as of Sep. 2024. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PaxMedica and its competitors.
Is PaxMedica's Stock Based Compensation too high?
PaxMedica's current Stock Based Compensation is MXN37.08 Mil. Overall, PaxMedica has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does PaxMedica's Stock Based Compensation compare to BTAX and NBIO?
PaxMedica's Stock Based Compensation of MXN37.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PaxMedica and its competitors. PaxMedica's current Stock Based Compensation is MXN37.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (MEX:PXMD) has a current Stock Based Compensation of MXN37.08 Mil. The current Stock Based Compensation is MXN37.08 Mil. PaxMedica's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For PaxMedica (MEX:PXMD), the current Stock Based Compensation is MXN37.08 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
20GF Score

Get the complete analysis for MEX:PXMD

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.69
Price